Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00490698 | Zoledronate With Atorvastatin in Renal Cell Carcinoma | PHASE2 | COMPLETED | 11 | — | — | Oct 1, 2006 | Jan 1, 2012 | Mar 18, 2013 | 1 | United States |
Time to skeletal events, defined as a metastatic site requiring radiotherapy or any surgical intervention (eg, embolization, radiofrequency ablation, intrathecal catheter placement) or complications from skeletal metastatic lesions (eg, pathologic fracture, spinal cord compression). Time to skeletal events monitored every 8 weeks for at least 1 year.
| Arm | Type | Description |
|---|---|---|
| Zoledronate + Atorvastatin | EXPERIMENTAL | Zoledronate 4 mg intravenous (IV) once every 4 Weeks + Atorvastatin 20 mg orally (PO) daily |
| Name | Type | Description |
|---|---|---|
| Zoledronate | DRUG | 4 mg IV Once Every 4 Weeks |
| Atorvastatin | DRUG | 20 mg PO Daily |
Inclusion Criteria: 1. Histologically confirmed renal cell carcinoma 2. Must have evidence of predominant bone metastases on X-rays, bone scan, MRI or CT scan. No requirement for bidimensionally measurable lesions. 3. Impending complications (such as pathological fractures and spinal cord compressi...